Press Release

Feb 23, 2024

YolTech Gains Patent for Advanced Base Editing Technology


[Shanghai, China, February 23, 2024] –YolTech Therapeutics, a biotech company developing in vivo gene editing therapies,  is thrilled to announce the approval of a significant patent for its cutting-edge base editing technology(YolBE), further cementing its position as a leader in genetic innovation. This breakthrough patent, granted by National Intellectual Property Administration (CNIPA), underscores the company's commitment to advancing precision genetic engineering, particularly in the field of in vivo gene therapy.

The patented base editing technology enables precise modifications at the DNA level, offering unprecedented accuracy and efficiency. This innovation holds immense promise in the realm of gene therapy, providing targeted solutions for genetic diseases with previously unattainable precision.

"This patent represents a major milestone in our journey towards advancing genetic medicine," stated Dr.Yuxuan Wu, founder and CEO. "It opens new doors for personalized treatments, bringing hope to patients with genetic disorders by enabling precise corrections at the molecular level."

With this patent, YolTech is poised to accelerate the development and deployment of its base editing platform for therapeutic applications. The company remains committed to leveraging innovative genetic solutions to address critical medical challenges and improve patient outcomes.

YolTech achieved another significant milestone as its investigational new drug (IND) application for an in vivo gene editing drug was approved by the NMPA earlier this month.

About YolTech

YolTech Therapeutics is a pioneering gene editing company dedicated to develop a robust gene editing medicines to treat patients with serious diseases, which has built leading high-throughput evolution platform and innovative LNP deliver system. It possesses strong capability of novel Cas and base editor discovery and exceptional in-house LNP production capacity for GMP manufactory, with independent intellectual property rights and core patent protection globally. It has created a pipeline with 10+ genetic medicines focusing on cardiovascular diseases, metabolic diseases, infectious diseases as well as more common and rare diseases. Clinical trial clearance has been received for its leading in vivo gene editing asset YOLT-201 in March 2024.

XML 地图 | Sitemap 地图